| Identification | Back Directory | [Name]
2-Propen-1-one, 1-[1-[5-chloro-2-[(1-ethyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-1,6-diazaspiro[3.5]non-6-yl]- | [CAS]
2673196-38-6 | [Synonyms]
JAK3/BTK-IN-4
2-Propen-1-one, 1-[1-[5-chloro-2-[(1-ethyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-1,6-diazaspiro[3.5]non-6-yl]- | [Molecular Formula]
C21H25ClN8O | [MOL File]
2673196-38-6.mol | [Molecular Weight]
440.93 |
| Hazard Information | Back Directory | [Uses]
JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)[1] | [References]
[1] Baoguo Zhang, et al. Pyrimidinopyrimidine and pentacyclic derivatives and their applications. Patent WO2021147953A1. |
|
|